Neuroscience research has been revolutionized by the use of recombinant viral vector technology from the basic, preclinical and clinical levels. Currently, multiple recombinant viral vector types are employed with each having its strengths and weaknesses depending on the proposed application. Helper-dependent adenoviral vectors (HdAd) are emerging as ideal viral vectors that solve a major need in the neuroscience field: (1) expression of transgenes that are too large to be packaged by other viral vectors and (2) rapid onset of transgene expression in the absence of cytotoxicity. Here, we describe the methods for large-scale production of HdAd viral vectors for in vivo use with neurospecific transgene expression.
You may also like
Insulin-like hormones critical for brain plasticity
August 7, 2023Max Planck Florida Institute for Neuroscience
A Butterfly Effect
July 27, 2023Max Planck Florida Institute for Neuroscience
How the brain slows down when we focus our gaze
June 28, 2023Max Planck Institute for Biological Cybernetics
Fruit fly’s complex symphony of vision
June 6, 2023Max Planck Institute for Biological Intelligence
How tasty is the food? Ask your brain!
June 6, 2023Max Planck Institute for Biological Intelligence
New study reveals ‘moonlighting’ function of part...
May 26, 2023Max Planck Institute for Brain Research